Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice

Lupus

Volumn 21, Issue 6, 2012, Pages 656-661

  Stirzaker, R A ^a   Biswas, P S ^a   Gupta, S ^a   Song, L ^a   Bhagat, G ^b   Pernis, A B ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

anti DNA antibodies; nephritis; Systemic lupus erythematosus

Indexed keywords

DNA ANTIBODY; FASUDIL; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLOMERULONEPHRITIS; LUPUS ERYTHEMATOSUS; LYMPHOCYTE; MORTALITY; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEINURIA; SPLEEN CELL; SURVIVAL RATE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADMINISTRATION, ORAL; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GLOMERULONEPHRITIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED NZB; MICE, MUTANT STRAINS; PROTEINURIA; RHO-ASSOCIATED KINASES;

EID: 84859921644     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312436862     Document Type: Article

References (17)

1. Eisenberg R. Mechanisms of autoimmunity. Immunol Res. 2003 ; 27: 203-218
2. Kong P, Odegard J, Bouzahzah F, et al. Intrinsic T cell defects in systemic autoimmunity. Ann N Y Acad Sci. 2003 ; 987: 60-67
3. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001 ; 1: 147-153
4. Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol. 2010 ; 2010: 943254-943254
5. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis. 2008 ; 67 (Suppl. 3). iii83 - iii86
6. Leonard WJ, Spolski R. Interleukin-21: A modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 2005 ; 5: 688-698
7. Brustle A, Heink S, Huber M, et al. The development of inflammatory T(h)-17 cells requires interferon-regulatory factor 4. Nat Immunol. 2007 ; 8: 958-966
8. Chen Q, Yang W, Gupta S, et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity. 2008 ; 29: 899-911
9. Huber M, Brustle A, Reinhard K, et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci U S A. 2008 ; 105: 20846-20851
10. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy?. Clin Cancer Res. 2009 ; 15: 2954-2961
11. Lech M, Weidenbusch M, Kulkarni OP, et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J Am Soc Nephrol. 2011 ; 22: 1443-1452
12. Biswas PS, Gupta S, Chang E, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest. 2010 ; 120: 3280-3295
13. Biswas PS, Gupta S, Chang E, Bhagat G, Pernis AB. Aberrant ROCK activation promotes the development of type I diabetes in NOD mice. Cell Immunol. 2011 ; 266: 111-115
14. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation. 2004 ; 109: 2234-2239
15. Liu Z, Bethunaickan R, Huang W, et al. Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum. 2011 ; 63: 219-229
16. Komers R. Rho kinase inhibition in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2011 ; 20: 77-83
17. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM. Rho-kinase inhibition: A novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 2010 ; 15: 622-629